Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: Case study of prostate cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1857-1866

  Xu, Juan ^a   Li, Chuan Xing ^a   Lv, Jun Ying ^a   Li, Yong Sheng ^a   Xiao, Yun ^a   Shao, Ting Ting ^a   Huo, Xiao ^a   Li, Xiang ^a   Zou, Yan ^a   Han, Qing Lian ^a   Li, Xia ^a   Wang, Li Hua ^a   Ren, Huan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADULT; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOFLUORESCENCE; MEDICAL DECISION MAKING; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SUPPORT VECTOR MACHINE;

ALGORITHMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, RNA;

EID: 80053955783     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0055     Document Type: Article

References (50)

1. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science 2005;310:1817-21.
2. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105.
3. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
4. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33:1290-7.
5. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol 2006;2:46.
6. Karp X, Ambros V. Developmental biology. Encountering microRNAs in cell fate signaling. Science 2005;310:1288-9.
7. Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet 2004;20:617-24.
8. Ulitsky I, Laurent LC, Shamir R. Towards computational prediction of microRNA function and activity. Nucleic Acids Res 38:e160.
9. Tsang JS, Ebert MS, van Oudenaarden A. Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell 2010;38:140-53.
10. Backes C, Meese E, Lenhof HP, Keller A. A dictionary on microRNAs and their putative target pathways. Nucleic Acids Res 2010;38:4476-86.
11. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10:297-308.
12. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int J Cancer 2008;122:969-77.
13. Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008;13:658-70.
14. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 2010;4:51.
15. Bandyopadhyay S, Mitra R, Maulik U, Zhang MQ. Development of the human cancer microRNA network. Silence 2010;1:6.
16. Xu J, Li CX, Li YS, Lv JY, Ma Y, Shao TT, et al. MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res 2011;39:825-36.
17. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010;20:589-99.
18. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, et al. An analysis of human microRNA and disease associations. PLoS One 2008;3:e3420.
19. Jiang Q, Hao Y, Wang G, Juan L, Zhang T, Teng M, et al. Prioritization of disease microRNAs through a human phenome-microRNAome network. BMC Syst Biol 2010;4 Suppl 1:S2.
20. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.
21. Shi XB, Tepper CG, White RW. MicroRNAs and prostate cancer. J Cell Mol Med 2008;12:1456-65.
22. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010;17:F1-17.
23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
24. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-8.
25. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
26. Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, Dalamagas T, et al. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res 2009;37:W273-6.
27. Hochberg Y, Benjamini Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300.
28. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009;37:D98-104.
29. Hu Z, Gallo SM. Identification of interacting transcription factors regulating tissue gene expression in human. BMC Genomics 2010;11:49.
30. Pennacchio LA, Loots GG, Nobrega MA, Ovcharenko I. Predicting tissue-specific enhancers in the human genome. Genome Res 2007;17:201-11.
31. Available from http://www.csie.ntu.edu.tw/~cjlin/libsvm. [cited 2010 Sep 24].
32. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-93.
33. Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recognition 1997;30:1145-59.
34. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet 2011;12:56-68.
35. Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005;33:W741-8.
36. Saini S, Majid S, Yamamura S, Tabatabai ZL, Suh SO, Shahryari V, et al. Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res 2011;17:5287-98.
37. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004;3:29.
38. Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R. Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells. Cell Cycle 2009;8:149-57.
39. Available from http://genome.cs.iastate.edu/supertree/download/biclique/ README.html. [cited Nov 6, 2010].
40. Wuchty S, Almaas E. Peeling the yeast protein network. Proteomics 2005;5:444-9.
41. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 Exerts tumor-suppressive functions in human prostate through downregulation of protein kinase Cepsilon. Cancer Res 2009;69:2287-95.
42. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration, and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011;38:1093-101.
43. Guillaud-Bataille M, Brison O, Danglot G, Lavialle C, Raynal B, Lazar V, et al. Two populations of double minute chromosomes harbor distinct amplicons, the MYC locus at 8q24.2 and a 0.43-Mb region at 14q24.1, in the SW613-S human carcinoma cell line. Cytogenet Genome Res 2009;124:1-11.
44. Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, et al. Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Res 2001;61:1611-8.
45. Song H, Li Y, Lee J, Schwartz AL, Bu G. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res 2009;69:879-86.
46. Song H, Bu G. MicroRNA-205 inhibits tumor cell migration through downregulating the expression of the LDL receptor-related protein 1. Biochem Biophys Res Commun 2009;388:400-5.
47. Craft CS, Romero D, Vary CP, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 2007;26:7240-50.
48. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
49. Lin DY. Evaluating statistical significance in two-stage genome-wide association studies. Am J Hum Genet 2006;78:505-9.
50. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al. Genome-wide association studies for complex traits: consensus, uncertainty, and challenges. Nat Rev Genet 2008;9:356-69.